Navigation Links
PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/18/2007

le improvement in the staining for dystrophin from muscle biopsies. Response did not appear to be dependent on type of nonsense mutation.

Blood levels of muscle-derived creatine kinase were also measured as assessments of muscle integrity. Statistically significant reductions in the concentrations of muscle-derived creatine kinase were observed during PTC124 treatment. In addition, several parents and teachers reported that boys participating in the study had improvements in terms of greater activity level and increased endurance during the study duration.

"We are very encouraged by these results, which show improvements in critical biomarkers of DMD," said presenter and study investigator, Carsten Bonnemann, M.D., Assistant Professor Neurology and Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine and Co-Director of the Neuromuscular Program, Children's Hospital of Philadelphia. "The combined in vitro and in vivo evidence of enhanced dystrophin expression and reduced muscle fragility offer signals of pharmacological activity that we hope to translate into potential clinical benefit for patients with DMD."

"Coupled with the emerging safety profile of PTC124, these data provide the impetus for moving forward rapidly to initiate longer-term studies for boys with DMD," said Langdon Miller, M.D., Chief Medical Officer of PTC. "We are actively working with our clinical investigators and the regulatory agencies to finalize plans for additional clinical trials and we look forward to commencing these studies in the coming months."

Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics added, "These results, combined with the data presented earlier this month at the Child Neurology Society meeting and North American Cystic Fibrosis Conference, further support our belief that PTC124 represents a paradigm shift in the treatment of genetic disorders. Our future plans for PTC124 inc
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)... - Unprecedented amount of research reflects ...ators worldwide to develop new treatments for ...nary session to highlight impact of Zometa(R), the...tients with early-stage breast cancer, - Four ora...y continuous, inhibitor of mTOR, including first r...
(Date:5/15/2008)... Excellent results obtained with a newly cleared...ary plaques of interest that are associated with ...g, BURLINGTON, Mass., May 15 /- Infr...umont Hospital in Royal Oak, Mich., have,successfu...in a patient,undergoing a cardiac catheterization....
(Date:5/15/2008)... BONITA SPRINGS, Fla., May 15 /- T...ecution of a Cooperative Research and,Development ...te (NCI) to,collaborate on clinical and preclinica...y in Phase I development. AFP-464 is converted to,...g in p53 activation and,apoptosis., This is part ...
(Date:5/15/2008)...- Top Line Data Expected soon after CEA Trial data... -, SAN FRANCISCO, May 15 /PRNewswire-Fi...AP ), a biotechnology company focused on the devel...cular disease, announced today that,it has complet...me (ACS),study. The ACS study is one of three Phas...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5PA Soldiers and Sailors Home Dedicates 32 Bed Dementia Alzheimers Unit 773 1Rain Man mice provide model for autism 771 1Rain Man mice provide model for autism 771 2An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 1An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 2An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 3An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 4An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 5Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings 435 1
... , GENEVA, Switzerland, April 27, 2007 –,Me...on,Pharmaceuticals S.p.A. (SWX: NWRN) announced to... present the results of the first,Phase III trial ...ne agonists (DA) in early Parkinson’s diseas...gy 59th Annual Meeting,to be held in Boston from 2...
...IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Co...opment company specializing in,anti-allergy medica... independent contract research organization that i...ocked data bases into a single,database before un-...equired to generate top-line results for Cobalis, ...
Other Medicine Technology:Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4Cobalis Expects to Report Phase III Top-Line Results in May 2
(Date:5/16/2008)...ffices of Howard G. Smith,announces a June 9, 2008...ecurities class action lawsuit filed on behalf of ...e common stock of Inverness Medical,Innovations, I... IMA ) in the,Company,s secondary public offering .... The shareholder lawsuit is pending in the United...
(Date:5/16/2008)...s want agency to act, not wait years , ,...umer drug ads on television should include a toll-...port adverse side effects, U.S. health experts sug...hat advises the U.S. Food and Drug Administration....A for print ads. At Friday,s meeting, the panel di...
(Date:5/16/2008)...HINGTON, May 16 /PRNewswire-USNewswire/ -- More th...s in the Greater Portland, Oregon and,Vancouver, W...ract as,Teamsters., "The Teamsters are pleased th...act that gives them job protection and a secure re... Jim Hoffa., The workers, both full-time and part...
(Date:5/16/2008)...fit from calcitriol, an oral form , , FR...vitamin D may cut the risk of death for people wit...ut one quarter, a new study suggests. , During...se being treated with calcitriol, an oral form of ...th lowered by 26 percent when compared with those ...
Breaking Medicine News(10 mins):Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...the British Government would be conducting a separ...nsultant radiologist in Ireland. // These clinical... scanner and have necessitated the recall of close...ir breast cancer examinations. The enquiry team w...
...ries is in the threat of ban on their export of se...food from Asian countries had the banned chemical ...el that the Canadian Food Inspection Agency should...d test all batches of imported seafood coming into...
... was brought home in a very uncomfortable manner w...e of the greatest footballers' died in London yest...after his own liver failed in the aftermath of his...case. Millions of people the world over, mostly ma...
...-1) is required for both cartilage and bone growth...d by the pituitary gland.// Deficiency of IGF-1 re...tabolic abnormalities including insulin resistance...IGF-1 drugs helps in production of IGF-1 in childr...
Other Medicine News:
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: